The investigators observed no benefit to adjuvant radiotherapy after radical prostatectomy in patients with prostate cancer in the phase 3 RADICALS-RT trial.
About one third of patients with esophageal cancer who have a compete response to neoadjuvant chemoradiotherapy may be able to avoid surgery. However, one expert questioned the study design.
Investigators reported that the Immunoscore biopsy, which quantifies immune cell tumor infiltration, is a strong predictor of recurrence during watchful waiting for rectal cancer.
Patients with early breast cancer and negative ultrasound axillary lymph node staging had similar locoregional relapse and distant DFS at 5 years whether or not they received SLN biopsy.